|

BEAM-302 Clinical Trials

1 actively recruiting trial across 1 location

Pipeline

Phase 1/2: 1

Top Sponsors

  • Beam Therapeutics Inc.1

Indications

  • Alpha 1-Antitrypsin Deficiency1
  • Liver Disease1

Birmingham, Alabama1 trial

A Study to Evaluate the Safety and Efficacy of BEAM-302 in Adult Patients With Alpha-1 Antitrypsin Deficiency (AATD)

Clinical Study Center

Phase 1/2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.